Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.28 is 70% above its 5-year average of -4.33, near the high end of its 5-year range (-5.70–-1.28).
69.23% above its 12-month average of -4.16.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.21.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.28
EARNINGS PER SHARE (EPS) AVG TTM
-4.16
EARNINGS PER SHARE (EPS) AVG 3Y
-4.49
EARNINGS PER SHARE (EPS) AVG 5Y
-4.33
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+69.23%
CURRENT VS 3Y AVG
+71.48%
CURRENT VS 5Y AVG
+70.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Phathom Pharmaceuticals, Inc.
Market Cap
$548.51M
Earnings Per Share (EPS)
-1.28
TTM Avg
-4.16
3Y Avg
-4.49
5Y Avg
-4.33
Market Cap
$557.32M
Earnings Per Share (EPS)
-0.45
TTM Avg
0.12
3Y Avg
-0.31
5Y Avg
-0.31
Market Cap
$538.01M
Earnings Per Share (EPS)
-0.57
TTM Avg
-0.57
3Y Avg
-0.87
5Y Avg
-0.89
Market Cap
$560.00M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$533.04M
Earnings Per Share (EPS)
-2.34
TTM Avg
-1.60
3Y Avg
-1.16
5Y Avg
-0.99
Market Cap
$531.98M
Earnings Per Share (EPS)
0.01
TTM Avg
0.08
3Y Avg
-2.02
5Y Avg
-4.00
Market Cap
$531.52M
Earnings Per Share (EPS)
-1.31
TTM Avg
-1.22
3Y Avg
-1.34
5Y Avg
-1.08
Market Cap
$529.58M
Earnings Per Share (EPS)
-0.51
TTM Avg
-1.09
3Y Avg
-1.66
5Y Avg
-1.43
Market Cap
$571.13M
Earnings Per Share (EPS)
2.13
TTM Avg
0.97
3Y Avg
0.08
5Y Avg
-0.20
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $548.51M | -1.28 | -4.16 | -4.49 | -4.33 |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | -0.45 | 0.12 | -0.31 | -0.31 |
| ProKidney Corp. (PROK)vs › | $538.01M | -0.57 | -0.57 | -0.87 | -0.89 |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | -2.34 | -1.60 | -1.16 | -0.99 |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 0.01 | 0.08 | -2.02 | -4.00 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | -1.31 | -1.22 | -1.34 | -1.08 |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | -0.51 | -1.09 | -1.66 | -1.43 |
| CorMedix Inc. (CRMD)vs › | $571.13M | 2.13 | 0.97 | 0.08 | -0.20 |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | -0.88 | -0.82 | -0.78 | -1.65 |
Trailing EPS (TTM)
$-1.28
Forward EPS (Est.)
$-0.71
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -3.03 |
| 2024-12-31 | -5.29 |
| 2023-12-31 | -3.93 |
| 2022-12-31 | -5.70 |
| 2021-12-31 | -4.00 |
| 2020-12-31 | -4.01 |
| 2019-12-31 | -8.48 |
| 2018-12-31 | -0.15 |
